Moreover, the prognostic role of COX-2 in BLCA is heterogeneous across studies: some cohorts report associations with poorer survival, whereas others do not support COX-2 as an independent marker [62]. The gene discussed is PTGS2; the disease is bladder transitional cell carcinoma.